News

Latest News

All
2016
2017
2018
2019
2020
2021
2022
2023
2024

April 4, 2024
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
March 20, 2024
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 7, 2024
Immunic to Participate in Investor and Scientific Conferences in March
February 29, 2024
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 22, 2024
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 15, 2024
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 1, 2024
Immunic to Participate in Investor and Scientific Conferences in February
January 5, 2024
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024
Immunic, Inc. Announces Private Placement of up to $240 Million
November 21, 2023
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis
November 14, 2023
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 2, 2023
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
October 26, 2023
Immunic to Participate in Scientific and Industry Conferences in November
October 16, 2023
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 15, 2023
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 11, 2023
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 9, 2023
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 4, 2023
Immunic to Participate in Scientific Conferences in October
September 6, 2023
Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 3, 2023
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 1, 2023
Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023
Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023
Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 6, 2023
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 4, 2023
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023
Immunic to Participate in Investor and Scientific Conferences in May
April 5, 2023
Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
March 2, 2023
Immunic to Participate in Investor and Scientific Conferences in March
February 23, 2023
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
February 22, 2023
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
February 16, 2023
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
February 9, 2023
Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
January 25, 2023
Immunic to Participate in Scientific and Investor Conferences in February
November 17, 2022
Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential
November 10, 2022
Immunic to Participate in Investor and Scientific Conferences in November and December
November 3, 2022
Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
October 20, 2022
Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
October 10, 2022
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 4, 2022
Immunic to Participate in Scientific and Industry Conferences in October
September 20, 2022
Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
September 1, 2022
Immunic, Inc. to Participate in Investor Conferences in September
August 16, 2022
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
August 4, 2022
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 2, 2022
Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
July 28, 2022
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
July 6, 2022
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
June 28, 2022
Immunic to Participate in Industry and Scientific Conferences in July
June 15, 2022
Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
June 8, 2022
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
June 2, 2022
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
May 10, 2022
Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
May 3, 2022
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
April 25, 2022
Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences
March 16, 2022
Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer
March 8, 2022
Immunic, Inc. to Participate in Investor and Scientific Conferences in March
February 24, 2022
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity
February 18, 2022
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis
February 17, 2022
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
February 8, 2022
Immunic, Inc. to Participate in Investor and Scientific Conferences in February
February 2, 2022
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
December 14, 2021
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
December 9, 2021
Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
November 23, 2021
Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference
November 18, 2021
Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
November 4, 2021
Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity
November 1, 2021
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update
October 28, 2021
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
October 27, 2021
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
October 14, 2021
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
September 30, 2021
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
September 28, 2021
Immunic, Inc. to Participate in Scientific and Investor Conferences in October
September 22, 2021
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
September 8, 2021
Immunic, Inc. to Participate in Investor and Scientific Conferences in September
August 6, 2021
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
August 3, 2021
Immunic, Inc. to Participate in Investor Conferences in August
July 19, 2021
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
July 15, 2021
Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
July 14, 2021
Immunic, Inc. Announces Proposed Public Offering of Common Stock
July 12, 2021
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
July 1, 2021
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
June 28, 2021
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
June 10, 2021
Immunic, Inc. to Participate in Industry and Investor Conferences in June
June 1, 2021
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
May 17, 2021
BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)
May 6, 2021
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
April 15, 2021
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838’s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
April 13, 2021
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
March 31, 2021
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
March 2, 2021
Immunic, Inc. to Participate in Industry and Investor Conferences in March
February 26, 2021
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
February 18, 2021
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
February 17, 2021
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
February 11, 2021
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
January 8, 2021
Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)
January 5, 2021
Immunic, Inc. to Participate in Investor Conferences in January
December 14, 2020
Immunic, Inc. Added to NASDAQ Biotechnology Index
December 2, 2020
BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)
November 24, 2020
Immunic, Inc. to Participate in Investor Conferences in December
November 17, 2020
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
November 10, 2020
Immunic, Inc. to Participate in Investor and Scientific Conferences in November
November 5, 2020
Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 2, 2020
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
October 20, 2020
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
September 29, 2020
Immunic, Inc. to Participate in Scientific Conferences in October
September 28, 2020
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
September 11, 2020
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
September 8, 2020
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
August 20, 2020
Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
August 10, 2020
Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 5, 2020
Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
August 3, 2020
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
August 2, 2020
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
July 30, 2020
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 29, 2020
Immunic, Inc. to Participate in Investor Conferences in August
July 27, 2020
Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19
June 22, 2020
Immunic, Inc. to Join Russell 3000® Index
June 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 10, 2020
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
June 10, 2020
Immunic, Inc. Announces Proposed Public Offering of Common Stock
June 9, 2020
Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020
Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
May 13, 2020
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020
Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
April 23, 2020
Immunic, Inc. Announces Pricing of $15 Million Financing
April 21, 2020
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
April 17, 2020
Immunic, Inc. Announces Changes to Executive Team
March 15, 2020
Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
February 11, 2020
Immunic, Inc. to Participate in Scientific and Investor Conferences in February
January 8, 2020
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
December 4, 2019
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn’s and Colitis Foundation’s IBD Innovate Conference
November 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
November 19, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
November 7, 2019
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
November 5, 2019
Immunic, Inc. to Participate in Industry and Investor Conferences in November
October 15, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
October 10, 2019
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
September 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in October
September 18, 2019
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
September 11, 2019
Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
September 5, 2019
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
September 3, 2019
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
August 12, 2019
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis
August 8, 2019
Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity
August 1, 2019
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
July 30, 2019
Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
July 16, 2019
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
June 24, 2019
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
June 21, 2019
Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update
June 4, 2019
Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway
May 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
May 9, 2019
Immunic, Inc. to Participate in Upcoming May Conferences
April 29, 2019
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
April 12, 2019
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
April 2, 2019
Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10
February 28, 2019
Immunic Therapeutics to Participate in Investor and Medical Conferences in March
February 26, 2019
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
February 6, 2019
Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11
January 7, 2019
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
November 5, 2018
Immunic enters into a global option and license agreement with Daiichi Sankyo
April 26, 2018
Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis
January 11, 2018
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis
December 12, 2017
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838
September 5, 2017
Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million
February 1, 2017
Immunic Adds EUR 4 Million in Funding to Further Boost Development
January 9, 2017
Immunic strengthens Management Team and Supervisory Board
September 28, 2016
Immunic acquires 4SC’s immunology portfolio
September 27, 2016
Immunic successfully closes 17.5 million Euro Series A financing round

Media and Investor Inquiries

Questions?

Get in touch.

Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09

Send an Email